Transplant Diagnostics Market worth $6.8 million | Revealing Emerging Players with New Data Insights
The transplant diagnostic market is projected to reach USD 6.8 billion in 2028 from USD 4.4 billion in 2022 with a CAGR of 7.4% during the forecast period. The high prevalence of infectious diseases, rising government funding and initiatives for transplant diagnostic programs, technological developments for different organ transplant and initiatives by an individual to donate organs is attributing to the growth of the transplant diagnostic market.
Request for Sample PDF @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=2531061
Key Market Players
Thermo Fisher Scientific has a strong geographic presence in more than 150 countries across North America, the Asia Pacific, Europe, and Latin America. Some of its major subsidiaries are Thermo Fisher Scientific Peru S.A., Laboratory Management Systems, Inc. (US), Open BioSystems, Inc. (US), Thermo Electron Australia Pty Limited, Lomb Scientific Pty Limited (Australia), Thermo Scientific Korea Ltd. (South Korea), Fisher Clinical Services Limited Liability Company (Russia), Fisher Clinical Services Japan K.K., and Thermo Fisher Scientific C.V. (Netherlands).
Thermo Fisher Scientific
Thermo Fisher Scientific is engaged in the development, manufacturing, and marketing of analytical instruments, reagents & consumables, equipment, and software products. The company operates its businesses through four segments, namely, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Services. The microbiology business under the company’s Specialty Diagnostics segment offers dehydrated and prepared culture media, collection and transport systems, microbiology instrumentation, and consumables to detect pathogens in blood, diagnostic, and rapid direct specimen tests, quality-control products, and associated products for microbiology laboratories.
Becton, Dickinson and Company
Becton, Dickinson and Company (BD) is engaged in the development, manufacture, and marketing of medical devices, instrument systems, and reagents. BD operates through three business segments—BD Medical, BD Life Sciences, and BD Interventional. The Life Sciences division is further divided into Diagnostic Systems, Preanalytical Systems, and Biosciences sub-divisions. The company offers transplant diagnostic products under the Diagnostic Systems segment of its Life Sciences division.
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (Bio-Rad) is engaged in developing, manufacturing, and supplying life sciences and clinical diagnostic tools and services. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Sciences segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
F.Hoffman-LA-Roche Ltd
F. Hoffmann-La Roche Ltd. (Roche) is a pharmaceutical and diagnostics company based in Switzerland. The company is engaged in the development, manufacturing, distribution, and marketing of therapeutic and diagnostic products. Roche operates through two business divisions, namely, Pharmaceuticals and Diagnostics.
Browse Complete Research Report @ https://www.marketsandmarkets.com/Market-Reports/global-transplant-diagnostics-market-2531061.html
North America to register major growth in the market during the forecast period
North America transplant diagnostic market is anticipated to register the highest growth over the forecast period of 2022 to 2028. North America accounted for the largest share of 45.5% of the transplant diagnostic market in 2022. This market is projected to reach USD 3.1 billion by 2028 from USD 2.0 billion in 2022, at a CAGR of 7.6% during the forecast period. North America holds 45.5% share of the total antimicrobial susceptibility testing market.
Recent Developments
· In February 2023, BD received FDA approval for BD Onclarity HPV assay in the serology testing segment
· In March 2023 BioRad received AQAC International and AFNOR approval for its iQ-Check kits.
· Hoffmann-La Roche Ltd. unveiled Cobas Infinity edge, a cloud-based point-of-care platform that is available everywhere, in January 2022. Practitioners in the healthcare industry can manage patient data thanks to advanced technology. This has aided the business in diversifying its product offering.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=2531061
About MarketsandMarkets™:
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian